The arrival of amivantamab presents a significant development for patients battling cancers exhibiting c-MET aberration. This novel antibody, a targeted blocker of dual MET kinase and also human epidermal growth factor https://sidneyyqjo062586.wikiexpression.com/6391504/amivantamab_a_potential_solution_for_c_met_associated_growths